Intervention Review

You have free access to this content

Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers

  1. Miranda van Rijen1,*,
  2. Marc Bonten2,
  3. Richard Wenzel3,
  4. Jan Kluytmans1

Editorial Group: Cochrane Wounds Group

Published Online: 8 OCT 2008

Assessed as up-to-date: 26 SEP 2010

DOI: 10.1002/14651858.CD006216.pub2


How to Cite

van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD006216. DOI: 10.1002/14651858.CD006216.pub2.

Author Information

  1. 1

    Amphia Hospital Breda, Laboratory for Microbiology and Infection Control, Breda, Netherlands

  2. 2

    University Medical Center Utrecht, Department of Internal Medicine and Infectious Diseases, Utrecht, Netherlands

  3. 3

    Virginia Commonwealth University, Department of Internal Medicine, Richmond, Virginia, USA

*Miranda van Rijen, Laboratory for Microbiology and Infection Control, Amphia Hospital Breda, PO Box 90158, Breda, 4800 RK, Netherlands. Mvrijen@amphia.nl.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 8 OCT 2008

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Boelaert 1989 {published data only}
  • Boelaert JR, De Smedt RA, De Baere YA, Godard CA, Matthys EG, Schurgers ML, et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrology, Dialysis, Transplantation 1989;4:278-81.
Garcia 2003 {published data only}
  • Garcia AM, Villa MV, Escudero ME, Gomez P, Vélez MM, Munera MI, et al. Use of nasal mupirocin for Staphylococcus aureus: effect on nasal carriers and nosocomial infections [Uso nasal de la mupirocina para Staphylococcus aureus: efecto en portadores y en infecciones nosocomiales]. Biomédica 2003;23:173-9.
Harbarth 1999 {published data only}
  • Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomised, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aures. Antimicrobial Agents and Chemotherapy 1999;43(6):1412-6.
Kalmeijer 2002 {published data only}
  • Kalmeijer MD, Coertjens H, De Baere GAJ, Stuurman A, Van Belkum A, Kluytmans JAJW. Postoperative wound infections in orthopedic surgery. The effect of mupirocin nasal ointment. Pharmaceutisch Weekblad 2001;136(20):730-1.
  • Kalmeijer MD, Coertjens H, Van Nieuwland-Bollen PM, Bogaers-Hofman D, De Baere GAJ, Stuurman A, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomised, placebo-controlled study. Clinical Infectious Diseases 2002;35(4):353-8.
Konvalinka 2006 {published data only}
Mup Study Group 1996 {published data only}
  • The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Journal of the American Society of Nephrology 1996;7(11):2403-8.
Perl 2002 {published data only}
  • Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. The New England Journal of Medicine 2002;346(24):1871-906.
Pérez-Fontan 1992 {published data only}
  • Pérez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Fernandez-Rivera C, Cao M, et al. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Advances in peritoneal dialysis 1992;8:242-5.
Wertheim 2004b {published data only}
  • Wertheim HFL, Vos MC, Ott A, Kluytmans JAJW, Vandenbroucke-Grauls CMJE, et al. Mupirocin prophylaxis for the prevention of nosocomial infections due to nasal carriers of Staphylococcus aureus is of no use in nonsurgical patients as yet. Nederlands Tijdschrift voor Geneeskunde 2005;149:350-5.
  • Wertheim HFL, Vos MC, Ott A, Voss A, Kluytmans JAJW, Vandenbroucke-Grauls MJE, et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients. Annals of Internal Medicine 2004;140:419-25.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Critchley 2006 {published data only}
  • Critchley IA. Eradication of MRSA nasal colonization as a strategy for infection prevention. Drug Discovery today: Therapeutic Strategies 2006;3(2):189-95.
Di Filippo 1999 {published data only}
  • Di Filippo A, Simonetti T. Endonasal mupirocin in the prevention of nosocomial pneumonia. Minerva Anestesiologica 1999;65(3):109-13.
Klaus 2002 {published data only}
  • Klaus G, Van Baum H, Wuhl E, Schaefer F, and European Pediatric Peritoneal Dialysis Study Group (EPPS). Efficacy of mupirocin prophylaxis in reducing the incidence of peritoneal dialysis (PD)-related Staphylococcus aureus infections in children on chronic PD: results of a double blind, placebo-controlled trial. Peritoneal Dialysis International. 2002; Vol. 22, issue 1:149.
Leigh 1993 {published data only}
  • Leigh DA, Joy G. Treatment of familial staphylococcal infection - comparison of mupirocin nasal ointment and chlorhexidine-neomycin (Naseptin) cream in eradication of nasal carriage. Journal of Antimicrobial Chemotherapy 1993;31(6):909-17.
Martin 1999 {published data only}
  • Martin JN, Perdreau-Remington F, Kartalija M, Pasi OG, Webb M, Gerberding JL, et al. A randomised clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. Journal of Infectious Diseases 1999;180(3):896-9.
Mody 2003 {published data only}
  • Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomised, double-blind, placebo-controlled trial. Clinical Infectious Diseases 2003;37(11):1467-74.
Niwa 1999 {published data only}
  • Niwa J, Yoshikawa O, Tanigawara T, Kubota T, Chiba M, Mikami T, et al. Prevention of MRSA spread in the neurological field: intranasal application of mupirocin calcium ointment. No Shinkei Geka - Neurological Surgery 1999;27(8):729-33.
Raz 1996 {published data only}
  • Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Archives of Internal Medicine 1996;156(10):1109-12.
Simor 2007 {published data only}
  • Simor AE, Philips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, et al. Randomised controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clinical Infectious Diseases 2007;44(2):178-85.
Sit 2007 {published data only}
  • Sit D, Kadiroglu AK, Kayabasi H, Yilmaz ME. Prophylactic intranasal mupirocin ointment in the treatment of peritonitis in continuous ambulatory peritoneal dialysis patients. Advances in Therapy 2007;24(2):387-93.
Suzuki 2003 {published data only}
Wasielewski 2003 {published data only}
  • Wasielewski S. Staphylococcus aureus: Does mupirocin nasal ointment prevent postoperative infections? [Schutzt mupirocin-nasensalbe vor postoperativen infecktionen?]. Deutsche Apotheker Zeitung 2003;143(18):50-2.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Bode 2010 {published data only}
  • Bode LGM, Kluytmans JAJW, Wertheim HFL, Bogaers D, Vandenbroucke-Grauls CMJE, Roosendaal R, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. New England Journal of Medicine  2010;362(1):9-17.
Golan 2010 {published data only}
  • Golan Y. Decolonization of nostrils and skin of nasal carriers of S. aureus at admission prevented hospital-associated infection. Annals of Internal Medicine  2010;152(10):JC5-9.
Jabbour 2010 {published data only}
  • Jabbour H, Madi Jebara S, Jabbour K, Yazigi A, Haddad F, Hayek G, et al. Does nasal decontamination reduce the incidence of infections after cardiac surgery?. Journal Medical Libanais - Lebanese Medical Journal  2010;58(2):65-70.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Fawley 2006
Francois 2003
  • Francois P, Pittet D, Bento M, Pepey B, Vaudaux P, Lew D, et al. Rapid detection of methicillin-resistant Staphylococcus aureus directly from sterile or nonsterile clinical samples by a new molecular assay. Journal of Clinical Microbiology 2003;41(1):254-60.
Henkel 1999
Higgins 2002
Higgins 2003
Kallen 2005
  • Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infection Control & Hospital Epidemiology 2005;26(12):916-22.
Kaplowitz 1988
  • Kaplowitz L, Comstock J, Landwehr D, Dalton H, Mayhall C. Prospective study on microbial colonization of the nose and skin and infection of the vascular access site in hemodialysis patients. Journal of Clinical Microbiology 1988;26(7):1257-62.
Kluytmans 1995
  • Kluytmans J, Mouton J, Yzerman E, Vandenbroucke-Grauls C, Maat A, Wagenvoort, et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. Journal of Infectious Diseases 1995;171(1):216-9.
Kluytmans 1997
  • Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clinical Microbiology Reviews 1997;10(3):505-20.
Laupland 2003
  • Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clinical Infectious Diseases 2003;37(7):933-8.
Lefebvre 2009
  • Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies.. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
Mangram 1999
  • Mangram A, Horan T, Pearson M, Silver L, Jarvis W. The Hospital Infection Control Practices Advisory Committee Guideline for the prevention of surgical site infection. Infection Control and Hospital Epidemiology 1999;20(4):247-80.
NNIS 2004
  • National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance System Report, data summary from January 1992 through June 2004. American Journal of Infection Control 2004;32:470-85.
Noskin 2005
  • Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M. The burden of Staphylococcus aureus to US hospitals: an analysis of the 2000-2001 nationwide inpatients sample database. Archives of Internal Medicine 2005;165(15):1756-61.
Paule 2004
  • Paule SM, Pasquariello AC, Hacek DM, Fisher AG, Thomson RB Jr, Kaul KL, et al. Direct detection of Staphyloccus aureus from adult and neonate nasal swab specimens using real-time polymerase chain reaction. Journal Molecular Diagnosis 2004;6(3):191-6.
Pittet 2000
SIGN 2008
Strippoli 2004
Trautmann 2008
Von Eiff 2001
Wertheim 2004a
  • Wertheim H, Vos M, Ott A, Van Belkum A, Voss A, Kluytmans J, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004;364:703-5.
Yu 1986
  • Yu VL, Goetz A, Wagener M, Smith PB, Rihs JD, Hanchett J, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. The New England Journal of Medicine 1986;315:91-6.
Yzerman 1996
  • Yzerman EP, Boelens HA, Tjhie JH, Kluytmans JA, Mouton JW, Verbrugh HA. APACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense. Journal of Infectious Diseases 1996;173(4):914-9.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
van Rijen 2008
  • van Rijen MML, Bonten M, Wenzel RP, Kluytmans JAJW. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: A systematic review. Journal of Antimicrobial Chemotherapy 2008;61(2):254-61.